Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
issued the following statement regarding the decision of the U.S. Court
of Appeals for the Federal Circuit. The decision validated the patent
for CUBICIN® (daptomycin for injection) that expires on June
15, 2016, but invalidated four patents with expiration dates in 2019 and
2020.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - November 12, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Cubicin MSD NYSE:MRK Source Type: news
Why I’m thankful for my daughter’s MRSA
“What time is surgery today?” Ellie, age 12, croaks. She hasn’t opened her eyes yet, but she knows she’s headed to the operating room … again. It may be the fourth surgery this month, maybe the fifth. We don’t know. What we do know is our routine has changed from soccer carpools and homework battles to twice-weekly trips to the operating room, where the orthopedic surgeon will slice open my baby girl’s thigh and attempt to wash out the deadly bacteria accumulating in her right femur and knee joint.
We’re trying to learn the new routine and master a new language. The vocabulary is demanding. There are proced...
Source: Thrive, Children's Hospital Boston - October 1, 2015 Category: Pediatrics Authors: Lisa Fratt Tags: All posts MRSA PICC line Source Type: news
Daptomycin Safe for Children With Skin InfectionsDaptomycin Safe for Children With Skin Infections
The potent antibiotic shows safety and efficacy for complicated skin infections in children, but safety concerns prevent studies in newborns. Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 19, 2015 Category: Dermatology Tags: Infectious Diseases News Source Type: news
Left-Sided MRSA Endocarditis Successfully Treated with a Combination of Daptomycin and Ceftaroline
Vancomycin is the recommended drug for treating endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA). Daptomycin is not inferior to vancomycin for treating MRSA bacteremia and right-sided endocarditis. There is synergistic activity between daptomycin and ceftaroline. Fifty percent of all cases of bacterial endocarditis are caused by S. aureus, half of which are caused by methicillin-resistant strains (1). A retrospective review of 133 cases of S. aureus endocarditis indicated an overall mortality rate of 38% for left-sided endocarditis in comparison to 17% for right-sided endocarditis (2). (Source: Cli...
Source: Clinical Microbiology Newsletter - March 24, 2015 Category: Microbiology Authors: Claudia D. Jarrin Tejada, Richard P. Wenzel Tags: Case Report Source Type: news
Patent Losses Put a Costly Damper on Merck's Cubist Buy
Just hours after Merck's $8.4 billion acquisition of Cubist Pharmaceuticals was announced, a federal court invalidated most of the patents protecting the Cubist's top-selling antibiotic, Cubicin. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 9, 2014 Category: Pharmaceuticals Source Type: news
Merck Statement Regarding CUBICIN Patent Litigation
Dateline City:
KENILWORTH, N.J.
Company Reaffirms Transaction To Proceed as Planned; Expected to Close in First Quarter of 2015
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the
following statement regarding the decision of the U.S. District Court
for the District of Delaware. The decision, which upheld the patent for
CUBICIN that expires on June 15, 2016 and invalidated four others, is
subject to appeal.
...
Source: Merck.com - Corporate News - December 9, 2014 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Court rules Hospira can launch generic Cubicin in 2016
(Reuters) - Hospira Inc can launch a generic version of Cubist Pharmaceuticals Inc 's leading drug Cubicin as soon as 2016, a federal judge has ruled. (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Cubicin (daptomycin for injection) 500 mg in 10 mL Single Use Vials...
On August 9, Cubist Pharmaceuticals, Inc. announced the recall of certain lots of Cubicin (daptomycin for injection) 500 mg due to the presence of particulate matter. In light of this news,...(PRWeb August 12, 2014)Read the full story at http://www.prweb.com/releases/2014/08/prweb12087103.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 12, 2014 Category: Pharmaceuticals Source Type: news
Nine Lots of IV Antibiotic Recalled (FREE)
By the Editors
Nine lots of the intravenous antibacterial Cubicin (daptomycin 500 mg), used for skin … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 11, 2014 Category: Primary Care Source Type: news
CUBICIN (daptomycin for injection) 500 mg in 10 mL Single Use Vials: Recall - Foreign Particulate Matter
Administration of particulate matter poses a potential safety risk to patients such as a thromboembolism or a life-threatening pulmonary embolism. (Source: FDA MedWatch)
Source: FDA MedWatch - August 9, 2014 Category: American Health Source Type: news
Cubicin (daptomycin for injection) 500 mg in 10 mL Single Use Vials: Recall - Presence Of Particulate Matter
The administration of a glass particulate poses a potential safety risk to patients such as a thromboembolism or a life-threatening pulmonary emboli. (Source: FDA MedWatch)
Source: FDA MedWatch - August 8, 2014 Category: American Health Source Type: news
Cubist Pharma recalls some vials of antibiotic Cubicin
(Reuters) - Cubist Pharmaceuticals Inc said it recalled some vials of its antibiotic Cubicin due to the potential presence of glass particles. (Source: Reuters: Health)
Source: Reuters: Health - August 6, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Announces Recall of Cubicin (daptomycin for injection):...
As the FDA announced on April 18, one lot of Cubicin (daptomycin for injection), by Cubist Pharmaceuticals, is recalled due to the presence of particular matter. In light of this news, AttorneyOne, a...(PRWeb April 25, 2014)Read the full story at http://www.prweb.com/releases/2014/04/prweb11795790.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 26, 2014 Category: Pharmaceuticals Source Type: news
Cubist Pharmaceuticals Issues Voluntary Recall Of Cubicin
Cubist Pharmaceuticals announced that it has issued a voluntary recall of one lot of Cubicin (daptomycin for injection) due to the presence of particulate matter, identified specifically as glass particles. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 21, 2014 Category: Pharmaceuticals Source Type: news
CUBICIN (daptomycin for injection) by Cubist Pharmaceuticals: Recall - Presence of Particulate Matter
Potential risk of thromboembolism, pulmonary emboli, phlebitis, mechanical block of the capillaries or arterioles, activation of platelets, subsequent generation of microthrombi, and emboli. (Source: FDA MedWatch)
Source: FDA MedWatch - April 18, 2014 Category: American Health Source Type: news
